Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HTI immunogen - Aelix Therapeutics

Next Previous
Drug Profile

HTI immunogen - Aelix Therapeutics

Alternative Names: DNA.HTI; HIV vaccine - Aelix Therapeutics; MVA.HTI

Latest Information Update: 10 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aelix Therapeutics
  • Class AIDS vaccines; Epitopes; Peptide vaccines; Synthetic vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II HIV infections

Most Recent Events

  • 19 Feb 2023 Immunigenicity and adverse event data from the phase II AELIX-003 trial presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023 (CROI-2023)
  • 16 Dec 2022 Gilead and AELIX Therapeutics complete a phase II (AELIX-003) trial for HIV infections (Combination therapy, Treatment experienced) in Spain (IM) (EudraCT2018-002125-30) (NCT04364035)
  • 25 Jul 2022 HTI immunogen is still in phase II trial for HIV infections Combination therapy, Treatment experienced) in Spain (IM) (EudraCT2018-002125-30) (NCT04364035)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top